Some CBD Products Rescheduled by DEA Under Controlled Substances Act

By: Sam Mendez and Heidi Urness, Strategic Legal Counsel at Cultiva Law The Drug Enforcement Administration (DEA) announced last Friday that certain Food and Drug Administration (FDA)-approved drugs that contain cannabidiol (CBD) are properly rescheduled as Schedule V drugs under the Controlled Substances Act (CSA). While this move is far from categorically rescheduling CBD – as…